Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

41. Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping

Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping 30386783 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping. 141 10.3389/fcvm.2018.00141 It is well-recognized that there is a need for medicine to migrate to a platform of delivering preventative care based on an individual's genetic make-up. The US National Research (...) Council, the National Institute of Health and the American Heart Association all support the concept of utilizing genomic information to enhance the clinical management of patients. It is believed this type of precision healthcare will revolutionize health management. This current attitude of some of the most respected institutes in healthcare sets the stage for the utilization of the haptoglobin (Hp) genotype to guide precision management in type 2 diabetics (DM). There are three main Hp genotypes: 1

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro

42. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. BACKGROUND: LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. We aimed to examine the efficacy and safety of co-stimulation of the GLP-1 and GIP receptors (...) with LY3298176 compared with placebo or selective stimulation of GLP-1 receptors with dulaglutide in patients with poorly controlled type 2 diabetes. METHODS: In this double-blind, randomised, phase 2 study, patients with type 2 diabetes were randomly assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1·5 mg), or placebo for 26 weeks. Assignment was stratified by baseline glycated haemoglobin A 1c (HbA 1c ), metformin use

Lancet2018

43. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. BACKGROUND: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. We aimed to evaluate the long-term effects of lorcaserin on diabetes prevention (...) and remission. METHODS: In this randomised, double-blind, placebo-controlled trial done in eight countries, we recruited overweight or obese patients (body-mass index ≥27 kg/m 2 ) with or at high risk for atherosclerotic vascular disease. Eligible patients were aged 40 years or older; patients at high risk for atherosclerotic vascular disease had to be aged 50 years or older with diabetes and at least one other risk factor. Patients were randomly assigned to receive either lorcaserin (10 mg twice daily

Lancet2018

44. Sleeve Gastrectomy Compared to Gastric Bypass as a Treatment for Type 2 Diabetes in those with a BMI < 35

Sleeve Gastrectomy Compared to Gastric Bypass as a Treatment for Type 2 Diabetes in those with a BMI < 35 "Sleeve Gastrectomy Compared to Gastric Bypass as a Treatment for Type " by Caitlyn Suelter < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Thirty million people in the United States have diabetes, of which, nearly 90% are considered overweight or obese (...) . Bariatric surgery, with the two most popular types being sleeve gastrectomy (SG) and gastric bypass (GB), is currently indicated as a treatment of type 2 diabetes (T2D) in those with a BMI > 35. However, recent studies have shown bariatric surgery to be an effective treatment in those with BMI Methods: An exhaustive literature search was completed using the following search engines: CINAHL-EBSCOhost, Web of Science, and MEDLINE-PubMed, and the following search terms: bariatric surgery, type 2 diabetes, and BMI

Pacific University EBM Capstone Project2018

45. Ertugliflozin (STEGLATRO) - type 2 diabetes mellitus

Ertugliflozin (STEGLATRO) - type 2 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 (...) Activity/submission type, control number Date submitted Decision and date Summary of activities Summary basis of decision for Date SBD issued: The following information relates to the original authorization of the new drug submission for . Drug identification number (DIN): 1 What was approved? 2 Why was approved? 3 What steps led to the approval of ? Submission Milestones: Submission milestone Date 4 What follow-up measures will the company take? 5 What post-authorization activity has taken place

Health Canada - Drug and Health Product Register2018

46. Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes

Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes 30039616 2018 08 24 1463-1326 2018 Jul 23 Diabetes, obesity & metabolism Diabetes Obes Metab Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. 10.1111/dom.13474 A slight increase in melanoma risk was observed among sodium-glucose co-transporter-2 (SGLT-2 (...) to the type of SGLT-2 inhibitor, type of control, ages of patients, race/ethnicity, and trial durations. For non-melanoma skin cancer risk, no significant difference was observed when all trials were combined (Peto OR, 0.70; 95% CI, 0.47-1.07; I 2 , 0%), while a significantly decreased risk was observed among trials with duration <52 weeks (Peto OR, 0.12; 95% CI, 0.02-0.59; I 2 , 0%). No evidence of publication bias was detected in the analyses. Current evidence from RCTs did not support a significantly

EvidenceUpdates2018

47. Risk of hypoglycaemia in people aged >/=65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus

Risk of hypoglycaemia in people aged >/=65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus 30216648 2018 09 14 1742-1241 72 10 2018 Oct International journal of clinical practice Int. J. Clin. Pract. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. e13240 10.1111/ijcp.13240 To investigate the risk of hypoglycaemia in people aged ≥65 years with type 2 diabetes (...) mellitus (T2DM) treated with linagliptin, in the largest pooled analysis performed to date. One thousand four hundred and eighty-nine patients aged ≥65 years with T2DM were pooled from 11 randomised, double-blind, parallel group, placebo-controlled trials evaluating linagliptin 5 mg alone, or in addition to various background therapies. The primary safety endpoint was the incidence of investigator-defined hypoglycaemia. There was no significant difference in the risk of hypoglycaemia between

EvidenceUpdates2018

48. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis

Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis 30058208 2018 09 03 1463-1326 2018 Jul 29 Diabetes, obesity & metabolism Diabetes Obes Metab Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. 10.1111/dom.13484 We conducted a systematic review and meta-analysis of randomized controlled trials to assess the effect of glucagon-like peptide-1 (...) receptor agonists (GLP-1 RAs) on microvascular endpoints in adult patients with type 2 diabetes. We included 60 studies with 60 077 patients. GLP-1 RAs marginally reduced urinary albumin-to-creatinine ratio compared with placebo or other antidiabetic agents (weighted mean difference - 2.55 mg/g; 95% confidence interval [CI] -4.37 to -0.73 and -5.52; -10.89 to -0.16, respectively) and had no clinically relevant effect on change in estimated glomerular filtration rate. Treatment with GLP-1 RAs did

EvidenceUpdates2018

49. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study 30019498 2018 08 17 1463-1326 2018 Jul 18 Diabetes, obesity & metabolism Diabetes Obes Metab A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. 10.1111/dom.13473 (...) To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c ≥7.0 to ≤9.5% (≥53 to ≤80 mmol/mol) and estimated glomerular filtration rate ≥60 to <90 mL/min/1.73m 2 on metformin (≥1500 mg/d) ± sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks

EvidenceUpdates2018

50. Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment

Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment 30003642 2018 08 30 1463-1326 2018 Jul 13 Diabetes, obesity & metabolism Diabetes Obes Metab Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. 10.1111/dom.13470 To investigate the impact of renal function on the safety and efficacy of insulin (...) glargine 300 U/mL (Gla-300) and insulin glargine 100 U/mL (Gla-100). A meta-analysis was performed using pooled 6-month data from the EDITION 1, 2 and 3 trials (N = 2496). Eligible participants, aged ≥18 years with a diagnosis of type 2 diabetes (T2DM), were randomized to receive once-daily evening injections of Gla-300 or Gla-100. Pooled results were assessed by two renal function subgroups: estimated glomerular filtration rate (eGFR) <60 and ≥60 mL/min/1.73 m 2 . The decrease in glycated haemoglobin

EvidenceUpdates2018

51. Carbohydrate quantity in the dietary management of type 2 diabetes: A systematic review and meta-analysis

Carbohydrate quantity in the dietary management of type 2 diabetes: A systematic review and meta-analysis 30098129 2018 09 10 1463-1326 2018 Aug 11 Diabetes, obesity & metabolism Diabetes Obes Metab Carbohydrate quantity in the dietary management of type 2 diabetes: A systematic review and meta-analysis. 10.1111/dom.13499 This systematic review and meta-analysis (registration number: CRD42013005825) compares the effects of low carbohydrate diets (LCDs) on body weight, glycaemic control, lipid (...) profile and blood pressure with the effects of higher carbohydrate diets (HCDs) in adults with type 2 diabetes. MEDLINE, EMBASE, CENTRAL, CINAHL, Food Science Source and SweMed+ databases were systematically searched to identify randomized controlled trials (duration ≥3 months) investigating the effects of an LCD compared to an HCD in the management of type 2 diabetes. Data were extracted and pooled using a random effects model and were expressed as mean differences and risk ratio. Subgroup analyses

EvidenceUpdates2018

52. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial

Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial 30084112 2018 09 05 1463-1326 2018 Aug 06 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes (...) and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial. 10.1111/dom.13491 To evaluate the efficacy and safety of a fixed-dose combination (FDC) of gemigliptin and rosuvastatin in patients with type 2 diabetes and dyslipidaemia. A total of 33 hospitals in Korea participated in this randomized, double-blind trial of diabetic patients with dyslipidaemia. A total of 290 participants were randomly assigned at a 1:1:1 ratio to receive an FDC of gemigliptin (50 mg

EvidenceUpdates2018

53. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular (...) death, myocardial infarction, or stroke. METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used

Lancet2018

54. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. BACKGROUND: The achievement of glycaemic control remains challenging for patients with type 1 diabetes. We assessed the effectiveness of day-and-night hybrid closed-loop insulin delivery compared with sensor-augmented pump therapy in people with suboptimally controlled type 1 diabetes aged 6 years and older. METHODS: In this open-label, multicentre, multinational, single-period (...) , parallel randomised controlled trial, participants were recruited from diabetes outpatient clinics at four hospitals in the UK and two centres in the USA. We randomly assigned participants with type 1 diabetes aged 6 years and older treated with insulin pump and with suboptimal glycaemic control (glycated haemoglobin [HbA 1c ] 7·5-10·0%) to receive either hybrid closed-loop therapy or sensor-augmented pump therapy over 12 weeks of free living. Training on study insulin pump and continuous glucose

Lancet2018 Full Text: Link to full Text with Trip Pro

55. Genetically-enhanced LPL mediated lipolysis, LDL cholesterol lowering alleles and risk of coronary disease and type 2 diabetes

Genetically-enhanced LPL mediated lipolysis, LDL cholesterol lowering alleles and risk of coronary disease and type 2 diabetes 30326043 2018 11 30 2380-6591 3 10 2018 Oct 01 JAMA cardiology JAMA Cardiol Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. 957-966 10.1001/jamacardio.2018.2866 Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical (...) at 58 independent genomic regions, including HMGCR, NPC1L1, and PCSK9. Odds ratio for coronary artery disease and type 2 diabetes. Of the 392 220 participants included, 211 915 (54.0%) were female, and the mean (SD) age was 57 (8) years. Triglyceride-lowering alleles in LPL were associated with protection from coronary disease (approximately 40% lower odds per SD of genetically lower triglycerides) and type 2 diabetes (approximately 30% lower odds) in people above or below the median

JAMA cardiology2018 Full Text: Link to full Text with Trip Pro

56. The development of multimorbidity during 16 years after diagnosis of type 2 diabetes

The development of multimorbidity during 16 years after diagnosis of type 2 diabetes 30363325 2018 11 14 2235-042X 8 1 2018 Jan-Dec Journal of comorbidity J Comorb The development of multimorbidity during 16 years after diagnosis of type 2 diabetes. 2235042X18801658 10.1177/2235042X18801658 The aims of this study were to (1) quantify the development and composition of multimorbidity (MM) during 16 years following the diagnosis of type 2 diabetes and (2) evaluate whether the effectiveness (...) of structured personal diabetes care differed between patients with and without MM. One thousand three hundred eighty-one patients with newly diagnosed type 2 diabetes were randomized to receive either structured personal diabetes care or routine diabetes care. Patients were followed up for 19 years in Danish nationwide registries for the occurrence of outcomes. We analyzed the prevalence and degree of MM based on 10 well-defined disease groups. The effect of structured personal care in diabetes patients

Journal of comorbidity2018 Full Text: Link to full Text with Trip Pro

57. Association between maternal gluten intake and type 1 diabetes in offspring: national prospective cohort study in Denmark.

Association between maternal gluten intake and type 1 diabetes in offspring: national prospective cohort study in Denmark. OBJECTIVE: To examine the association between prenatal gluten exposure and offspring risk of type 1 diabetes in humans. DESIGN: National prospective cohort study. SETTING: National health information registries in Denmark. PARTICIPANTS: Pregnant Danish women enrolled into the Danish National Birth Cohort, between January 1996 and October 2002, MAIN OUTCOME MEASURES (...) : Maternal gluten intake, based on maternal consumption of gluten containing foods, was reported in a 360 item food frequency questionnaire at week 25 of pregnancy. Information on type 1 diabetes occurrence in the participants' children, from 1 January 1996 to 31 May 2016, were obtained through registry linkage to the Danish Registry of Childhood and Adolescent Diabetes. RESULTS: The study comprised 101 042 pregnancies in 91 745 women, of whom 70 188 filled out the food frequency questionnaire. After

BMJ2018

58. Illness perception of adolescents with well-controlled type 1 diabetes mellitus

Illness perception of adolescents with well-controlled type 1 diabetes mellitus 30245842 2018 11 14 2055-1029 5 2 2018 Jul-Dec Health psychology open Health Psychol Open Illness perception of adolescents with well-controlled type 1 diabetes mellitus. 2055102918799968 10.1177/2055102918799968 In this study, to explore the illness perceptions of adolescents with well-controlled type 1 diabetes mellitus in South Africa, semi-structured interviews were conducted with nine, purposively selected (...) adolescents (mean = 13.9 years; median = 12). Themes that emerged from the thematic analysis include the following: accepting diabetes and the diabetes care plan as part of their lives; viewing diabetes as manageable and as their responsibility; and the important role of gaining information on diabetes and diabetes management. These perceptions contributed to adherence to diabetes care plans and should be explored and developed among adolescents with type 1 diabetes mellitus to improve their diabetes

Health psychology open2018 Full Text: Link to full Text with Trip Pro

59. Education can restore awareness of low blood glucose in people with type 1 diabetes

Education can restore awareness of low blood glucose in people with type 1 diabetes Signal - Education can restore awareness of low blood glucose in people with type 1 diabetes Dissemination Centre Discover Portal NIHR DC Discover Education can restore awareness of low blood glucose in people with type 1 diabetes Published on 20 October 2015 This systematic review found that a range of educational and technological interventions could help adults with type 1 diabetes regain awareness of when (...) they have low blood glucose (hypoglycaemia). Nearly one in every three adults with type 1 diabetes stops noticing low blood sugar levels. This means they cannot take action quickly to prevent a medical crisis. People with low awareness of their blood sugar levels are six times more likely to have severe hypoglycaemia, which can cause fits and even coma. The authors recommended an approach to restoring awareness that starts with structured teaching about flexible insulin therapy and adjusting insulin

NIHR Dissemination Centre2018

60. Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes

Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes 30250846 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes. 117 10.3389/fcvm.2018.00117 Glyoxalase-1 (GLO1) is a ubiquitously expressed cytosolic protein which plays a role in the natural maintenance of cellular health and is abundantly (...) expressed in human skeletal muscle. A consequence of reduced GLO1 protein expression is cellular dicarbonyl stress, which is elevated in obesity, insulin resistance and type 2 diabetes (T2DM). Both in vitro and pre-clinical models suggest dicarbonyl stress per se induces insulin resistance and is prevented by GLO1 overexpression, implicating a potential role for GLO1 therapy in insulin resistance and type 2 diabetes (T2DM). Recent work has identified the therapeutic potential of novel natural agents

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro